Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Janssen Cilag International
Sponsor

Janssen Cilag International

Belgium Turnhoutseweg 30, 2340 Beerse, Belgium

About the sponsor

Multiple myeloma, relapsed or refractory myeloma, chronic lymphocytic leukemia, small lymphocytic lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, myelodysplastic neoplasms, and AL amyloidosis are prominent areas of interest, alongside studies in mantle cell lymphoma and other B-cell malignancies.

  • Multiple myeloma and plasma cell disorders
  • B-cell non-Hodgkin lymphoma and CLL/SLL
  • Acute leukemia and myelodysplastic neoplasms

Research also extends to warm autoimmune hemolytic anemia and other haematology-focused conditions.

About Specializations

Janssen Cilag International runs clinical trials in conditions such as Plasma cell myeloma, Colitis ulcerative, Non-small cell lung cancer, Crohn's disease, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

137 clinical trials

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

Recruiting
Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Major depression

Recruiting
InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:SELTOREXANT
  • Sponsor:Janssen Cilag International

Plasma cell myeloma refractory

Recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Janssen Cilag International

Colitis ulcerative

Recruiting
Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Non-small cell lung cancer

Recruiting
Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Plasma cell myeloma refractory

Recruiting
Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Janssen Cilag International

Crohn's disease

Recruiting
Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Systemic lupus erythematosus

Recruiting
InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Plasma cell myeloma refractory

Recruiting
Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Janssen Cilag International

Hormone-refractory prostate cancer

Recruiting
Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Janssen Cilag International

Myasthenia gravis

Recruiting
Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Janssen Cilag International

Crohn's disease

Recruiting
InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ICOTROKINRA
  • Sponsor:Janssen Cilag International

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).